BioCentury
ARTICLE | Company News

BrainStorm, Octane Medical Group deal

December 24, 2012 8:00 AM UTC

The companies partnered to co-develop a proprietary bioreactor to produce BrainStorm's NurOwn NTF stem cells using Octane Biotech Inc.'s Automated Cell & Tissue Engineering System (ACTES) technology. The project is funded by a three-year grant from the Canada-Israel Industrial Research and Development Foundation (CIIRDF). The ACTES technology integrates bioreactors, biosensors and bioprocessing to enable routine GMP production of cell-based products for clinical therapeutics. Octane Biotech is an affiliate of Octane Medical. The companies could not be reached for details. ...